Naples Money Management LLC Takes Position in Pfizer Inc. (NYSE:PFE)

Naples Money Management LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,478 shares of the biopharmaceutical company’s stock, valued at approximately $43,000.

Several other large investors have also made changes to their positions in PFE. Worth Asset Management LLC bought a new stake in shares of Pfizer in the first quarter worth about $29,000. Briaud Financial Planning Inc purchased a new position in shares of Pfizer during the third quarter valued at approximately $30,000. Sanctuary Wealth Management L.L.C. purchased a new position in shares of Pfizer during the fourth quarter valued at approximately $50,000. Mizuho Securities Co. Ltd. purchased a new position in shares of Pfizer during the third quarter valued at approximately $34,000. Finally, VisionPoint Advisory Group LLC boosted its position in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 2.4 %

Shares of PFE stock opened at $25.99 on Friday. The stock has a 50 day moving average of $27.11 and a 200 day moving average of $28.68. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a market cap of $147.17 billion, a P/E ratio of 72.19, a P/E/G ratio of 1.14 and a beta of 0.61. Pfizer Inc. has a twelve month low of $25.23 and a twelve month high of $40.37.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. During the same period last year, the company earned $1.14 earnings per share. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.24 EPS for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on PFE shares. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. Finally, TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Twelve analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.